UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~December~~January 1320, ~~2019~~2020

ZANDER THERAPEUTICS, INC.

(Exact name of small business issuer as specified in its charter)

Nevada	47-4321638
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

Commission File No. 333-220790

4700 Spring Street, St 304, La Mesa, California 91942

(Address of Principal Executive Offices)

(619) 702 1404

(Issuer’s telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8 1.0102 ~~Other~~Termination ~~Events~~of a Material Definitive Agreement.

On January ~~December 13~~20, ~~2019~~2020 ~~a complaint was filed in the Superior Court of California, County of San Diego against~~ Zander Therapeutics, Inc. (~~"Company") ,~~ the “Company~~'s Chairman, Regen Biopharma, Inc ("Regen"~~”), and ~~Does~~BST ~~1-50~~Partners ~~by ChemDiv,~~ Inc. ~~("Plaintiff")~~agreed ~~alleging Breach~~that ~~of Contract, Unfair Business Practices under~~ the ~~California~~month ~~Business~~to ~~and~~month ~~Professions Code, and Bad Faith Denial of~~sublease aby ~~Contract ( alleged solely against Regen~~ and ~~DOE~~between ~~defendants) stemming from contract research work performed by~~ the ~~Plaintiff for the~~ Company and ~~contract~~BST ~~research~~Partners, ~~performed~~Inc. bywhereby the ~~Plaintiff~~Company ~~for~~subleased ~~Regen.~~office ~~The~~space ~~Plaintiff is also seeking a declaration~~ from ~~the~~ ~~court~~BST ~~that the Plaintiff retains full and complete ownership~~Partners, ~~title,~~Inc. ~~use,~~at ~~and~~4700 ~~all rights without any limits to the work,~~Spring ~~tangible property~~Street, ~~intellectual~~St ~~property~~304, ~~and~~La ~~any~~Mesa, ~~other~~California ~~product~~91942 orshall ~~by-product~~terminate ofas ~~the work performed by Plaintiff for the Company and Regen. The action arises from approximately $1.2 million dollars~~ of ~~unpaid~~1pm ~~invoices~~Pacific ~~("Unpaid~~Standard ~~Invoices")~~Time ~~due~~on ~~and~~January ~~payable to~~22, ~~the Plaintiff~~2020.

~~The outcome of this legal~~Item ~~proceeding~~5.02 ~~may~~Departure ~~adversely affect the Company’s financial condition and operations and may also result in loss~~ of ~~control~~Directors ~~by the~~or ~~Company~~Certain ~~of intellectual property controlled by the Company.~~ Officers

~~The~~On ~~Company~~January ~~and~~22, ~~Regen~~2020 ~~are~~David ~~under~~Koos ~~common~~resigned ~~control.~~as ~~David~~Chairman ~~Koos~~of ~~serves~~the asBoard of Directors, Chief Executive Officer of and ~~Chairman~~from ofany and all offices held at Zander Therapeutics, Inc. ( the ~~Board~~“Company”) as of ~~Regen~~1 ~~and~~pm Pacific Standard Time on January 22, 2020 ( “Effective ~~the~~Date ~~Company~~and Time”). As of the Effective Date and Time Todd S. Caven, ~~serves~~the asCompany’s Chief Financial Officer and is a ~~Director~~member of the Board of ~~Regen~~Directors of the Company, shall be the Company’s sole officer and member of the Company’s Board of Directors.

2Item 9.01 Exhibits

SIGNATURE

Exhibit 99.1	Letter of resignation
Exhibit 99.2	Termination of Sublease

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~2

	ZANDER THERAPEUTICS, INC.
Dated: January 6, 2020	By: /s/ David Koos
	David Koos
	Chief Executive Officer

SIGNATURE

3Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ZANDER THERAPEUTICS, INC.

Dated: January 22, 2020	By: /s/ David Koos
	David Koos
	Chief Executive Officer

Filing Compare · Zander Therapeutics, Inc